Liu Zhao-Yang, Wang De-Chang, Fu Zhao-Di, Liu Hong-Yan, Liang Zhi, Cheng Dong-Wan, Liang Jun-Lin, Liang Jian-Min
Cancer Institute, Chinese Academy of Medical Sciences and Peking Union of Medical College, Beijing 100021, P. R. China.
Ai Zheng. 2006 Aug;25(8):983-9.
BACKGROUND & OBJECTIVE: SHEN QI JIN KANG (SQJK) capsule is a complex preparation, consisting of effective components extracted from radix astragali, ginseng, curcuma, etc. It has been demonstrated to be able to decrease tumor volume, increase life quality and prolong survival time in clinic application. The study was to investigate the antitumor effects of SQJK capsule in vivo and in vitro, and further explore the possible mechanisms.
The proliferation of cancer cells treated with SQJK was measured by MTT assay in twelve cell lines; cell apoptosis was observed under an electric microscopic and detected by flow cytometry in MCF-7 and MA891 cells; altered telomerase activity in A549 cells was examined by a telomerase activity detection kit. Furthermore, the inhibitory effect of SQJK on tumors was also surveyed in vivo by using mice and nude mice models bearing transplanted tumors.
Inhibitory concentration 50% (IC(50)) of SQJK on A549, U251, MCF-7, Ketr-3, EJ, and A2780 cells was 30.954 microg/ml, 31.746 microg/ml, 37.220 microg/ml, 40.366 microg/ml, 41.398 microg/ml, and 45.083 microg/ml, respectively. Typical sub-G1 peaks, indicating the occurrence of apoptosis, were revealed in MA891and MCF-7 cells treated with SQJK. Morphological changes including cell shrinkage and condensation of chromosomes were observed. The telomerase activity of A549 was inhibited after 48 h of SQJK treatment. SQJK 1.8 g/kg inhibited the weights of transplanted tumors (MA891, H22, S180 in mice and PC-3 (M), MCF-7 and Ketr-3 in nude mice) by 50.84%, 48.91%, 40.88%, 62.50%, 47.83% and 30.06%, while SQJK 3.6 g/kg inhibited the weights by 56.49%, 59.62%, 55.70%, 70.76%, 58.66% and 50.18%, respectively.
SQJK has demonstrated antitumor bioactivity both in vitro and in vivo, which may be related to its effects of inducing apoptosis and decreasing telomerase activity.
参芪金康（SQJK）胶囊是一种复方制剂，由黄芪、人参、姜黄等提取的有效成分组成。临床应用已证明其能减小肿瘤体积、提高生活质量并延长生存时间。本研究旨在探讨参芪金康胶囊体内外的抗肿瘤作用，并进一步探索其可能的作用机制。
采用MTT法检测参芪金康处理的癌细胞在12种细胞系中的增殖情况；在电镜下观察MCF-7和MA891细胞的凋亡情况，并通过流式细胞术进行检测；使用端粒酶活性检测试剂盒检测A549细胞中端粒酶活性的变化。此外，还通过荷瘤小鼠和裸鼠模型在体内研究参芪金康对肿瘤的抑制作用。
参芪金康对A549、U251、MCF-7、Ketr-3、EJ和A2780细胞的半数抑制浓度（IC50）分别为30.954μg/ml、31.746μg/ml、37.220μg/ml、40.366μg/ml、41.398μg/ml和45.083μg/ml。在用参芪金康处理的MA891和MCF-7细胞中观察到典型的亚G1峰，表明细胞发生凋亡。观察到包括细胞皱缩和染色体凝聚在内的形态学变化。参芪金康处理48小时后，A549细胞的端粒酶活性受到抑制。参芪金康1.8g/kg使移植瘤重量（小鼠体内的MA891、H22、S180和裸鼠体内的PC-3（M）、MCF-7和Ketr-3）分别降低50.84%、48.91%、40.88%、62.50%、47.83%和30.06%，而参芪金康3.6g/kg使移植瘤重量分别降低56.49%、59.62%、55.70%、70.76%、58.66%和50.18%。
参芪金康在体内外均显示出抗肿瘤生物活性，这可能与其诱导凋亡和降低端粒酶活性的作用有关。
